© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Based on recent data, Bicycle Therapeutics plc (BCYC) shows an Average True Range (ATR) of 0.35 and an Enterprise Value of 480.46M. Its average trading volume over the past 3 months is 303.78K, indicating liquidity. These fundamental metrics provide insight into BCYC's underlying financial health and market activity.
Bicycle Therapeutics plc (BCYC) technical indicators as of January 1, 2026: the SMA 20 is -0.33%, SMA 50 at -0.44%, and SMA 200 at -8.05%. The RSI 14 value is 50.89, suggesting its current momentum. These technical analysis signals help assess BCYC's price trends and potential future movements.
Bicycle Therapeutics plc (BCYC) stock performance overview as of January 1, 2026: The 52-week high is $15.47 (currently -54.23% below), and the 52-week low is $6.03 (currently 17.41% above). Over the past year, BCYC's performance is -51.8%, compared to the S&P 500's 12.29% change.
According to market data, Bicycle Therapeutics plc (BCYC) stock's recent performance metrics show that over the last month, BCYC is -5.35%, with a Year-to-Date (YTD) performance of -49.43%. Over the past year, the stock has seen a -51.8% change. These figures summarize BCYC's price movements across various periods, reflecting its historical returns.
According to current financial data, BCYC stock's P/E (TTM) ratio is -1.93, which compares to the S&P 500's P/E of 32.59. The sector median P/E is -1.24. Key valuation ratios for BCYC, including P/S (17.09), P/B (0.78), and P/FCF (-2.00), offer insights into how the company is valued relative to its earnings, sales, book value, and free cash flow.